MCK

CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.

The Texas Stock Exchange (TXSE) is more than a regional milestone — it is a shift in competition among U.S. capital markets.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson Corporation (MCK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

McKesson NYSE: MCK executives said the company's first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses.

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

McKesson NYSE: MCK discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter.

McKesson operates within a US pharma distribution oligopoly, generating $5B+ in FCF and aggressively repurchasing shares. The oncology segment is driving growth, with a 31% YoY revenue increase and strategic acquisitions reinforcing the shift toward higher-margin businesses. Despite negative shareholder equity from buybacks and opioid liabilities, MCK maintains strong liquidity, low leverage, and disciplined capital returns.